Literature DB >> 10857944

Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group.

P J Dyck1, P J Dyck1, T S Larson, P C O'Brien, J A Velosa.   

Abstract

OBJECTIVE: To test quantitative sensation testing (QST) patterns of hypoesthesia and hyperalgesia as indicators of diabetic polyneuropathy (DPN) and its severity RESEARCH DESIGN AND METHODS: We used Computer-Assisted Sensory Examination IV; characterized the QST results of the foot of each patient in three diabetic cohorts (approximately 1,500 patients) as hyperesthetic (< or = 2.5th percentile), low-normal (2.5th-50th percentiles), high-normal (50th-97.5th percentiles), or hypoesthetic (> or = 97.5th percentile); and tested associations with symptoms, impairments, and test abnormalities.
RESULTS: Overall neuropathic impairment was most severe in the pancreas-renal transplant and nerve growth factor cohorts, but it was much less severe in the population-based Rochester Diabetic Neuropathy Study (RDNS) cohort. The frequency distribution of sensory abnormalities mirrored this difference. When the QST spectra of diabetic cohorts were compared with those of the control subject cohort for vibration and cooling sensations, the only abnormality observed was hypoesthesia, which was expressed as an increased number of subjects with values at or above the 97.5th percentile or by an increased percentage of cases with high-normal values. Symptoms and impairments of DPN were significantly more frequent in the subjects with values at or above the 97.5th percentile than in the subjects whose values were between the 50th and 97.5th percentiles. For heat pain (HP) sensation thresholds (intermediate pain severity [HP:5], pain threshold [HP:0.5], and pain-stimulus response slope [HP:5-0.5]), an increased frequency of both hypoalgesia and hyperalgesia was observed (especially in the RDNS cohort). Steeper pain-stimulus response slopes were significantly associated with sensory symptoms, including severity of pain.
CONCLUSIONS: 1) Decreased vibratory sensation (hypoesthesia) appears to be characteristic of mild DPN, whereas panmodality hypoesthesia is characteristic of severe DPN. 2) A shift of vibratory and cold detection thresholds (and also of attributes of nerve conduction and a measure of autonomic dysfunction) from low-normal (2.5th-50th percentiles) to high-normal (50th-97.5th percentiles) appears to precede overt expression of DPN and to thereby provide evidence of subclinical abnormality 3) Heat stimulus-induced hyperesthesia (low thresholds) occurs especially in mild DPN, and, because it correlates with DPN symptoms and impairments, it must be attributed to hyperalgesia rather than to supersensitivity Therefore, hypoalgesia or hyperalgesia may be an indicator of early DPN.

Entities:  

Mesh:

Year:  2000        PMID: 10857944     DOI: 10.2337/diacare.23.4.510

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  34 in total

Review 1.  Mechanisms of neuropathic pain.

Authors:  James N Campbell; Richard A Meyer
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

Review 2.  Abnormal endogenous pain modulation is a shared characteristic of many chronic pain conditions.

Authors:  Roland Staud
Journal:  Expert Rev Neurother       Date:  2012-05       Impact factor: 4.618

3.  Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes.

Authors:  Viktor R Drel; Pal Pacher; Igor Vareniuk; Ivan A Pavlov; Olga Ilnytska; Valeriy V Lyzogubov; Seth R Bell; John T Groves; Irina G Obrosova
Journal:  Int J Mol Med       Date:  2007-12       Impact factor: 4.101

4.  Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor.

Authors:  N A Calcutt; J D Freshwater; A P Mizisin
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

Review 5.  Diabetic painful and insensate neuropathy: pathogenesis and potential treatments.

Authors:  Irina G Obrosova
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

6.  A Comparative study of examination scores and quantitative sensory testing in diagnosis of diabetic polyneuropathy.

Authors:  A Mythili; K Dileep Kumar; K A V Subrahmanyam; K Venkateswarlu; Raju G Butchi
Journal:  Int J Diabetes Dev Ctries       Date:  2010-01

Review 7.  Painful and painless diabetic neuropathy: one disease or two?

Authors:  Vincenza Spallone; Carla Greco
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

8.  Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy.

Authors:  Dong Hwee Kim; Steven R Zeldenrust; Phillip A Low; Peter J Dyck
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

9.  PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy.

Authors:  Irina G Obrosova; Weizheng Xu; Valeriy V Lyzogubov; Olga Ilnytska; Nazar Mashtalir; Igor Vareniuk; Ivan A Pavlov; Jie Zhang; Barbara Slusher; Viktor R Drel
Journal:  Free Radic Biol Med       Date:  2007-10-03       Impact factor: 7.376

10.  The role of nerve growth factor in the prophylaxis and treatment of diabetic foot ulcers.

Authors:  Elisavet K Tiaka; Nikolaos Papanas; Anastassios C Manolakis; Efstratios Maltezos
Journal:  Int J Burns Trauma       Date:  2011-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.